Zamicastat is primarily investigated for its potential therapeutic applications in treating cardiovascular diseases, particularly those related to pulmonary arterial hypertension (PAH). It functions as a dopamine β-hydroxylase inhibitor, which helps in reducing the levels of norepinephrine, a neurotransmitter that can contribute to high blood pressure and heart strain. By modulating this pathway, Zamicastat aims to alleviate symptoms and improve cardiac function in patients suffering from PAH. Its development represents a targeted approach to managing this condition, offering hope for more effective treatment options. Research continues to explore its efficacy and safety in clinical settings.